Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.670
+0.030 (1.14%)
Nov 20, 2024, 4:00 PM EST - Market closed
Moleculin Biotech Employees
Moleculin Biotech had 18 employees as of December 31, 2023. The number of employees decreased by 1 or -5.26% compared to the previous year.
Employees
18
Change (1Y)
-1
Growth (1Y)
-5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,675,000
Market Cap
7.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ontrak | 104 |
Mustang Bio | 80 |
Syros Pharmaceuticals | 68 |
Edesa Biotech | 16 |
Galecto | 13 |
Cardio Diagnostics Holdings | 9 |
Coeptis Therapeutics Holdings | 7 |
Evoke Pharma | 4 |
MBRX News
- 2 days ago - New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PRNewsWire
- 6 days ago - Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PRNewsWire
- 9 days ago - Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PRNewsWire
- 9 days ago - Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 15 days ago - Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - PRNewsWire
- 16 days ago - Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - PRNewsWire
- 5 weeks ago - Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - PRNewsWire